S.agalactiae antigens I + II

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds bacterium or component thereof or substance produced...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S184100, C435S069100, C435S252300, C435S320100, C435S325000, C536S023700, C530S300000, C530S350000

Reexamination Certificate

active

07438912

ABSTRACT:
The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof fromS. agalactiae, methods for isolating such antigens and specific uses thereof.

REFERENCES:
patent: WO 02/059148 (2002-08-01), None
Stalhammar-Carlemalm et al J.Exp.Med. 1993, 177, 1593-1603.
Ellis, R.W. (Chapter 29 of “Vaccines” Plotkin, 5.A. et al. (eds) published by W. B. Saunders company (Philadelphia) in 1988.
Accession nuber ABP28545.
Accession No. ADV88412.
Brodeur et al., “Identification of group B streptococcal Sip protein, which elicites cross-protective immunity,”Infection and Immunity, 68:5610-5618, 2000.
Database EMBL accession No. AE14198.
Database EMBL accession No. AL766844.
Etz et al., “Identification of in vivo expressed vaccine candidate antigens fromStaphyolococcus aureus,” Proc. Natl. Acad. Sci. USA, 99:6573-6578, 2002.
Glaser et al., “Genome sequence ofStreptococcus agalactia, a pathogen causing invasive neonatal disease,”Molecular Microbiology, 45:1499-1513, 2002.
Henics et al., “Small-fragment genomic libraries for the display of putative epitopes from clinically significant pathogens,”Biotechniques, 35:196-200,202,20, 2003.
Hughes et al., “Novel protein vaccine candidates against Group B streptococcal infection identified using alkaline phosphate fusions,”FEMS Microbiology Letters, 222:263-271, 2003.
Klade, “Proteomics approaches towards antigen discovery in vaccine development,”Current Opinion in Molecular Therapeutics, 4:216-224, 2002.
Larsson et al., “Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine,”Vaccine, 17:454-458, 1999.
Michel et al., “Cloned alpha and beta C-protein antigens of group B Streptococci elicit protective immunity,”Infection and Immunity, 59:2023-2028, 1991.
Moyo et al., “The putative R1 protein of streptococcus agalactiae as serotype marker and target of protective antibodies,”APMIS, 109:842-848, 2001.
Tettelin et al., “Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype VStreptococcus agalactiae,” Proc. Natl. Acad. Sci. USA, 99:12391-12396, 2002.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

S.agalactiae antigens I + II does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with S.agalactiae antigens I + II, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and S.agalactiae antigens I + II will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4007958

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.